

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**New Horizon Health Limited**  
**諾輝健康**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6606)**

**CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS;  
CHANGE IN THE COMPOSITION OF THE INDEPENDENT SPECIAL  
COMMITTEE;  
CHANGE IN THE COMPOSITION OF THE BOARD COMMITTEES;  
AND  
CONTINUED SUSPENSION OF TRADING**

The Board hereby announces that:

- (1) Prof. Hong Wu has resigned from her position as an independent non-executive Director, the chairperson of the Remuneration Committee and a member of the Nomination Committee;
  - (2) Ms. Jiangnan Kong (孔江南) has been appointed as an independent non-executive Director and a member of the Independent Special Committee;
  - (3) Ms. Jiangnan Kong has been appointed as the chairperson of the Remuneration Committee; and
  - (4) Ms. Jiangnan Kong has been appointed as a member of the Nomination Committee,
- each with effect from October 1, 2024.

**RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**” and each, a “**Director**”) of New Horizon Health Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) announces the followings:

Prof. Hong Wu (“**Prof. Wu**”) has resigned as an independent non-executive Director, the chairperson of the remuneration committee of the Company (the “**Remuneration Committee**”) and a member of the nomination committee of the Company (the “**Nomination Committee**”) with effect from October 1, 2024 due to her personal health reason.

Prof. Wu has confirmed that she has no disagreement with the Board and there are no matters relating to her resignation which need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its gratitude and appreciation to Prof. Wu for her contribution to the Company during her term of office.

## **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board further announces that Ms. Jiangnan Kong (孔江南) (“**Ms. Kong**”) has been appointed as an independent non-executive Director with effect from October 1, 2024.

The biographical details of Ms. Kong are as follows:

**Ms. Jiangnan Kong** (孔江南), aged 53, has been working as a freelance legal and business consultant since May 2023. From November 2013 to April 2023, she served as the Chief Legal Officer at the Overseas Department of Beijing Enterprises Water Group Limited (stock code: 0371. HK). During this period, she also held the position of General Manager at the General Department of BEWG (M) Sdn. Bhd., the Malaysian subsidiary of Beijing Enterprises Water Group Limited. Between 2004 and 2011, Ms. Kong was an associate at Baker & McKenzie in Beijing and a senior associate at Jones Day in Shanghai. Prior to that, between 1999 and 2004, she worked as an associate at Blake, Cassels & Graydon in Toronto and an associate at Squire, Sanders & Dempsey LLP in Beijing.

Ms. Kong obtained her bachelor’s degree of laws from Peking University in the PRC in 1992. She then obtained her master’s degree of laws from University of Cambridge in the U.K. in 1996. After that, Ms. Kong obtained the bachelor’s degree of laws from University of Windsor in Canada in 1999. Ms. Kong also obtained the executive master of business administration (EMBA) degree from Quantic School of Business and Technology in 2021.

Ms. Kong was admitted to the Bar of Ontario, Canada in 2001 and the New York State Bar in 2002.

Ms. Kong will enter into an appointment letter as an independent non-executive Director with the Company for an initial term of three years, and will be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Company’s articles of association. As specified in the appointment letter, the remuneration for Ms. Kong is US\$3,300 per month, which is determined by the Board (the decision of which was based on the recommendation of the Remuneration Committee) with reference to her duties and responsibilities in the Company, the qualification and experience, the prevailing market rate and the remuneration policy of the Company. Such remuneration is subject to review by the Remuneration Committee and the Board from time to time.

Save as disclosed above, as at the date of this announcement, Ms. Kong (i) does not hold any other positions with the Company or other members of the Group; (ii) does not have any relationships with any other Directors, senior management, substantial shareholders or controlling shareholders (as respectively defined in the Rules Governing the Listing of Securities (the “**Listing Rules**”) on the Stock Exchange) of the Company; (iii) has not at any time during the three years preceding the date of this announcement served nor is currently serving as a director of any other publicly listed companies in Hong Kong or overseas; and (iv) does not have any interests in the shares, underlying shares and debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Ms. Kong has confirmed that (i) she has satisfied all the criteria for independence as set out in Rule 3.13 of the Listing Rules; (ii) she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected persons (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment.

Save as disclosed above, there is no other information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules (particularly in relation to sub-paragraphs (h) to (v) therein), nor are there any other matters that need to be brought to the attention of the shareholders of the Company and the Stock Exchange relating to the appointment of Ms. Kong.

The Board would like to take this opportunity to welcome Ms. Kong in joining the Board.

#### **CHANGE IN THE COMPOSITION OF THE INDEPENDENT SPECIAL COMMITTEE**

Reference is made to the announcement of the Company dated April 8, 2024 (the “**Announcement**”). Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcement. As stated in the Announcement, the Board has established the Independent Special Committee which is comprised of Mr. Danke Yu, Prof. Hong Wu, Dr. Donald Kwok Tung Li, Mr. Lau Ngai Kee Ricky and Ms. Ng Weng Sin, and is chaired by Mr. Lau Ngai Kee Ricky. Following the resignation of Prof. Wu, Ms. Kong has been appointed as a member of the Independent Special Committee with effect from October 1, 2024.

Following the abovementioned change, the Independent Special Committee is composed of five independent non-executive Directors, namely Mr. Lau Ngai Kee Ricky as the chairperson, and Mr. Danke Yu, Dr. Donald Kwok Tung Li, Ms. Ng Weng Sin and Ms. Jiangnan Kong as members.

#### **CHANGE IN THE COMPOSITION OF THE REMUNERATION COMMITTEE**

Ms. Jiangnan Kong, an independent non-executive Director, has been appointed as the chairperson of the Remuneration Committee with effect from October 1, 2024.

Following the abovementioned change, the Remuneration Committee is composed of one executive Director and two independent non-executive Directors, namely Ms. Jiangnan Kong as the chairperson, and Dr. Yiyou Chen and Mr. Danke Yu as members.

## **CHANGE IN THE COMPOSITION OF THE NOMINATION COMMITTEE**

Ms. Jiangnan Kong, an independent non-executive Director, has been appointed as a member of the Nomination Committee with effect from October 1, 2024.

Following the abovementioned change, the Nomination Committee is composed of one executive Director and two independent non-executive Directors, namely Mr. YeQing Zhu as the chairperson, and Mr. Danke Yu and Ms. Jiangnan Kong as members.

## **CONTINUED SUSPENSION OF TRADING**

Trading in the Company's shares on the Stock Exchange has been suspended since March 28, 2024 and will remain suspended pending fulfilment of the Resumption Guidance (as defined in the announcement of the Company dated May 28, 2024).

**Shareholders and potential investors should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**New Horizon Health Limited**  
**Mr. YeQing ZHU**  
*Chairman*

Hong Kong, September 27, 2024

*As at the date of this announcement, the Board comprises Mr. YeQing ZHU as Chairman and executive Director, Dr. Yiyou CHEN as executive Director, Mr. Naxin YAO as non-executive Director, and Mr. Danke YU, Prof. Hong WU, Dr. Donald Kwok Tung LI, Mr. LAU Ngai Kee Ricky and Ms. NG Weng Sin as independent non-executive Directors.*